Natural killer (NK) cell assay within bladder mucosa of patients bearing transitional cell carcinoma (TCC) after interferon (IFN) therapy: An immunohistochemical and ultrastructural study

International Journal of Clinical Pharmacology Research

Volumn 17, Issue 1, 1997, Pages 31-36

  Natsis, K ^a   Toliou, Th ^b   Stravoravdi, P ^b   Kirtsis, P ^c   Grekou, A ^b   Barich, A ^b   Konstantinidis, E ^c   Gigis, P ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

^c General Hospital of Drama   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CD57 ANTIGEN; MONOCLONAL ANTIBODY;

ARTICLE; BLADDER MUCOSA; CELL ULTRASTRUCTURE; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; LAMINA PROPRIA; MALE; NATURAL KILLER CELL; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON ALFA-2B; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MICROSCOPY, ELECTRON; MUCOUS MEMBRANE; SURGICAL PROCEDURES, OPERATIVE; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0031370720     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Torti M.F., Lum L.B. Superficial bladder cancer: Risk of recurrence and potential role for interferon therapy. Cancer, 57, 613, 1987.
2. Lum L.B., Totri M.F. Adjuvant intravesicular pharmacotherapy for superficial bladder cancer. J. Natl. Cancer Inst., 83, 682, 1991.
3. Holstein A.F., Sandmann S., Bressel M., Davidoff M.S. Reinvestigation of the transitional epithelium (urothelium) of the human ureter. Ann. Anat., 176, 109, 1994.
4. Rosenberg S.A. Lymphokine-activated killer cells: A new approach to immunotherapy of cancer. J, Natl. Cancer Inst., 75, 595, 1985.
5. Molto L., Alvarez-Mon M., Carballido J., Olivier C., Gimeno F., Manzano L. Use of Intracavitary Interferon-a2b in prophylactic treatment of patients with superficial bladder cancer. Cancer, 75, 2720, 1995.
6. Toliou Th., Stravoravdi P., Polyzonis M., Vakalikos J. Natural killer cell activation after interferon administration in patients with MRCC: An ultrastructural and immunohistochemical study. Eur. Ural., 29, 252, 1996.
7. Robertson S.M., Ritz J. Biology and clinical relevance of human natural killer cells. Blood, 76, 2421, 1990.
8. Welsch R.M. Natural killer cells and interferon. CRC Crit. Rev. Immunol., 5, 55, 1984.
9. Zarcone D., Prasthofer F.E., Malavasi F, Pistola V., Lo Buglio F.A., Grossi C. Ultrastructural analysis of human natural killer cell activation. Blood, 69, 1725, 1987.